ICR criticises NICE rejection of olaparib for advanced prostate cancer 06 Sep 2022 The Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not to recommend olaparib for previously treated, hormone-relapsed metastatic prostate cancer. Find out more Show/Hide
All patients’ cancers should be genetically profiled to improve care, say leading health experts 08 Aug 2022 The NHS should offer all cancer patients genetic profiling of their cancers at diagnosis and during treatment to shape care and track how the disease evolves, a consensus group of leading experts has concluded. Find out more Show/Hide
EMA recommends olaparib for treatment of high-risk, early breast cancer 27 Jun 2022 The Institute of Cancer Research, London, strongly welcomes the news that olaparib has been recommended by the European Medicines Agency (EMA) to treat people with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes. Find out more Show/Hide
The ICR responds to NICE’s recommendation not to approve abiraterone as first-line treatment for advanced prostate cancer 15 Jul 2021
ICR welcomes NICE’s decision to reassess abiraterone as first-line treatment for advanced prostate cancer 29 Oct 2020
ICR welcomes approval of immunotherapy for head and neck cancer in Scotland but warns of ‘home nations lottery’ 07 Sep 2020
Approval of targeted therapies first line for prostate cancer ‘will ease COVID-19 pressures’ 06 May 2020